PortfoliosLab logoPortfoliosLab logo
BIOT.L vs. BCOM.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BIOT.L vs. BCOM.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) and L&G All Commodities UCITS ETF - USD Accumulating ETF (BCOM.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BIOT.L achieves a 8.27% return, which is significantly lower than BCOM.L's 20.90% return.


BIOT.L

1D
0.31%
1M
7.79%
6M
7.56%
YTD
8.27%
1Y
33.81%
3Y*
10.20%
5Y*
2.83%
10Y*

BCOM.L

1D
0.64%
1M
2.17%
6M
16.01%
YTD
20.90%
1Y
30.69%
3Y*
12.81%
5Y*
10.51%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

BIOT.L vs. BCOM.L - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BIOT.L
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF
8.27%36.47%-5.31%-9.28%-8.41%-3.60%28.29%13.02%-8.12%
BCOM.L
L&G All Commodities UCITS ETF - USD Accumulating ETF
20.90%16.19%4.43%-7.25%15.63%27.35%-2.99%5.14%-10.71%

Correlation

The correlation between BIOT.L and BCOM.L is -0.16, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.16

Correlation (3Y)
Calculated over the trailing 3-year period

-0.01

Correlation (5Y)
Calculated over the trailing 5-year period

0.10

Correlation (All Time)
Calculated using the full available price history since Jan 18, 2018

0.16

The correlation between BIOT.L and BCOM.L shifts across timeframes, from -0.16 (1 year) to 0.16 (all time), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BIOT.L vs. BCOM.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIOT.L
BIOT.L Risk / Return Rank: 6767
Overall Rank
BIOT.L Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
BIOT.L Sortino Ratio Rank: 6464
Sortino Ratio Rank
BIOT.L Omega Ratio Rank: 5555
Omega Ratio Rank
BIOT.L Calmar Ratio Rank: 8383
Calmar Ratio Rank
BIOT.L Martin Ratio Rank: 7070
Martin Ratio Rank

BCOM.L
BCOM.L Risk / Return Rank: 5959
Overall Rank
BCOM.L Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
BCOM.L Sortino Ratio Rank: 6161
Sortino Ratio Rank
BCOM.L Omega Ratio Rank: 6666
Omega Ratio Rank
BCOM.L Calmar Ratio Rank: 5151
Calmar Ratio Rank
BCOM.L Martin Ratio Rank: 4949
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIOT.L vs. BCOM.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) and L&G All Commodities UCITS ETF - USD Accumulating ETF (BCOM.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BIOT.LBCOM.LDifference
Sharpe ratioReturn per unit of total volatility

-0.11

Sortino ratioReturn per unit of downside risk

+0.06

Omega ratioGain probability vs. loss probability

1.28

1.32

-0.04

Calmar ratioReturn relative to maximum drawdown

3.52

2.10

+1.42

Martin ratioReturn relative to average drawdown

10.12

6.65

+3.47

BIOT.L vs. BCOM.L - Sharpe Ratio Comparison

The current BIOT.L Sharpe Ratio is 1.67, which is comparable to the BCOM.L Sharpe Ratio of 1.78. The chart below compares the historical Sharpe Ratios of BIOT.L and BCOM.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BIOT.L vs. BCOM.L - Drawdown Comparison

The maximum BIOT.L drawdown since its inception was -34.44%, which is greater than BCOM.L's maximum drawdown of -31.65%. Use the drawdown chart below to compare losses from any high point for BIOT.L and BCOM.L.


Loading charts...

Drawdown Indicators


BIOT.LBCOM.LDifference

Max Drawdown

Largest peak-to-trough decline

-34.44%

-31.65%

-2.79%

Max Drawdown (1Y)

Largest decline over 1 year

-9.55%

-14.33%

+4.78%

Max Drawdown (3Y)

Largest decline over 3 years

-19.91%

-14.33%

-5.58%

Max Drawdown (5Y)

Largest decline over 5 years

-33.80%

-26.27%

-7.53%

Current Drawdown

Current decline from peak

-5.72%

-8.29%

+2.57%

Average Drawdown

Average peak-to-trough decline

-13.31%

-11.63%

-1.68%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.33%

4.53%

-1.20%

Volatility

BIOT.L vs. BCOM.L - Volatility Comparison

L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) has a higher volatility of 6.08% compared to L&G All Commodities UCITS ETF - USD Accumulating ETF (BCOM.L) at 4.53%. This indicates that BIOT.L's price experiences larger fluctuations and is considered to be riskier than BCOM.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BIOT.LBCOM.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.08%

4.53%

+1.55%

Volatility (6M)

Calculated over the trailing 6-month period

15.54%

14.82%

+0.72%

Volatility (1Y)

Calculated over the trailing 1-year period

20.18%

16.93%

+3.25%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

18.62%

16.81%

+1.81%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

19.50%

15.35%

+4.15%

BIOT.L vs. BCOM.L - Expense Ratio Comparison

BIOT.L has a 0.49% expense ratio, which is higher than BCOM.L's 0.15% expense ratio.


Dividends

BIOT.L vs. BCOM.L - Dividend Comparison

Neither BIOT.L nor BCOM.L has paid dividends to shareholders.


Tickers have no history of dividend payments

Frequently Asked Questions


BIOT.L and BCOM.L have a correlation of -0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, BCOM.L is cheaper at 0.15% per year. The better choice depends on whether you care most about return, fees, risk, or income.

BCOM.L is cheaper with a 0.15% expense ratio, compared with 0.49% for BIOT.L.

BIOT.L is categorized as Health & Biotech Equities, while BCOM.L is Commodities. BIOT.L tracks Solactive Pharma Breakthrough Value Index Net Total Return, while BCOM.L tracks Bloomberg Commodity Index Total Return. Their fees differ too: 0.49% for BIOT.L and 0.15% for BCOM.L.

Portfolio Optimizer

Find the right allocation for BIOT.L and BCOM.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer